Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Bio-Rad Laboratories stock in Canada | $764.62
Own Bio-Rad Laboratories shares in just a few minutes.
Bio-Rad Laboratories is a medical devices business based in the US. Bio-Rad Laboratories stocks (BIO.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $672.7 – an increase of 0.63% over the previous week. Bio-Rad Laboratories employs 7,700 staff and has a trailing 12-month revenue of around $2.9 billion.
How to buy shares in Bio-Rad Laboratories
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BIO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Bio-Rad Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Bio-Rad Laboratories?
- Has coronavirus impacted Bio-Rad Laboratories shares?
- Bio-Rad Laboratories shares summary
- Compare share dealing platforms
- Is Bio-Rad Laboratories stock a buy or sell?
- Bio-Rad Laboratories performance over time
- Can I short Bio-Rad Laboratories shares?
- Is Bio-Rad Laboratories suitable for ethical investing?
- Are Bio-Rad Laboratories shares over-valued?
- Bio-Rad Laboratories's financials
- How volatile are Bio-Rad Laboratories shares?
- Does Bio-Rad Laboratories pay a dividend?
- Have Bio-Rad Laboratories shares ever split?
- Other common questions
How has Coronavirus impacted Bio-Rad Laboratories's stock price?
Since the stock market crash in March caused by coronavirus, Bio-Rad Laboratories's stock price has had significant positive movement.
Its last market close was $764.62, which is 47.62% up on its pre-crash value of $400.5 and 147.15% up on the lowest point reached during the March crash when the stocks fell as low as $309.3801.
If you had bought $1,000 worth of Bio-Rad Laboratories stocks at the start of February 2020, those stocks would have been worth $897.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,102.71.
Bio-Rad Laboratories stock priceUse our graph to track the performance of BIO stocks over time.
Bio-Rad Laboratories shares at a glance
|Latest market close||$764.62|
|52-week range||$507.22 - $832.70|
|50-day moving average||$760.26|
|200-day moving average||$687.19|
|Wall St. target price||$856.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$134.05|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Bio-Rad Laboratories price performance over time
|1 week (2021-10-21)||0.63%|
|1 month (2021-09-24)||-4.77%|
|3 months (2021-07-28)||8.31%|
|6 months (2021-04-28)||17.81%|
|1 year (2020-10-28)||36.67%|
|2 years (2019-10-28)||123.90%|
|3 years (2018-10-26)||184.47%|
|5 years (2016-10-28)||385.01%|
Is Bio-Rad Laboratories under- or over-valued?
Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Rad Laboratories's P/E ratio
Bio-Rad Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Bio-Rad Laboratories shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Bio-Rad Laboratories's PEG ratio
Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0375. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Rad Laboratories's EBITDA
Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $711.5 million.
The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.
Bio-Rad Laboratories financials
|Revenue TTM||$2.9 billion|
|Operating margin TTM||19.98%|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||2.85%|
|Return on equity TTM||42.7%|
|Market capitalisation||$22.3 billion|
TTM: trailing 12 months
Shorting Bio-Rad Laboratories shares
There are currently 469,192 Bio-Rad Laboratories shares held short by investors – that's known as Bio-Rad Laboratories's "short interest". This figure is 12% down from 532,999 last month.
There are a few different ways that this level of interest in shorting Bio-Rad Laboratories shares can be evaluated.
Bio-Rad Laboratories's "short interest ratio" (SIR)
Bio-Rad Laboratories's "short interest ratio" (SIR) is the quantity of Bio-Rad Laboratories shares currently shorted divided by the average quantity of Bio-Rad Laboratories shares traded daily (recently around 151352.25806452). Bio-Rad Laboratories's SIR currently stands at 3.1. In other words for every 100,000 Bio-Rad Laboratories shares traded daily on the market, roughly 3100 shares are currently held short.
However Bio-Rad Laboratories's short interest can also be evaluated against the total number of Bio-Rad Laboratories shares, or, against the total number of tradable Bio-Rad Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Rad Laboratories's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bio-Rad Laboratories shares in existence, roughly 20 shares are currently held short) or 0.0222% of the tradable shares (for every 100,000 tradable Bio-Rad Laboratories shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Rad Laboratories.
Bio-Rad Laboratories's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bio-Rad Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bio-Rad Laboratories's total ESG risk score
Total ESG risk: 23.57
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bio-Rad Laboratories's overall score of 23.57 (as at 01/01/2019) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bio-Rad Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bio-Rad Laboratories's environmental score
Environmental score: 6.03/100
Bio-Rad Laboratories's environmental score of 6.03 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bio-Rad Laboratories's social score
Social score: 16.8/100
Bio-Rad Laboratories's social score of 16.8 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bio-Rad Laboratories's governance score
Governance score: 10.75/100
Bio-Rad Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bio-Rad Laboratories's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bio-Rad Laboratories scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bio-Rad Laboratories has, for the most part, managed to keep its nose clean.
Bio-Rad Laboratories share dividends
We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months.
Have Bio-Rad Laboratories's shares ever split?
Bio-Rad Laboratories's shares were split on a 2:1 basis on 8 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Rad Laboratories shares which in turn could have impacted Bio-Rad Laboratories's share price.
Bio-Rad Laboratories share price volatility
Over the last 12 months, Bio-Rad Laboratories's shares have ranged in value from as little as $507.22 up to $832.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 0.8873. This would suggest that Bio-Rad Laboratories's shares are less volatile than average (for this exchange).
Bio-Rad Laboratories overview
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.
Stocks similar to Bio-Rad Laboratories
Frequently asked questions
Bio-Rad Laboratories in the news
Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Bio-Rad Laboratories Moves Up In Market Cap Rank, Passing Darden Restaurants
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy ARK 21Shares Bitcoin ETF (ARKB) stock in Canada when it goes public
Everything we know about the ARK 21Shares Bitcoin ETF IPO, plus information on how to buy in.
How to buy ARK 21Shares Bitcoin Futures Strategy ETF (ARKA) stock in Canada when it goes public
Everything we know about the ARK 21Shares Bitcoin Futures Strategy ETF IPO, plus information on how to buy in.
How to buy FaZe Clan (FAZE) stock in Canada when it goes public
Everything we know about the FaZe Clan IPO, plus information on how to buy in.
How to buy Valkyrie Bitcoin Strategy ETF (BTF) stock in Canada
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
How to buy VanEck Bitcoin Strategy ETF (XBTF) stock in Canada when it goes public
Everything we know about the VanEck Bitcoin Strategy ETF IPO, plus information on how to buy in.
How to buy Trump Media and Technology Group stock in Canada when it goes public
Everything we know about the Trump Media and Technology Group IPO, plus information on how to buy in.
How to buy ProShares Bitcoin Strategy ETF (BITO) stock in Canada
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.